These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AMAG’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that AMAG Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for AMAG
In the past 30 days, 1 estimate has gone higher for AMAG Pharmaceuticals. The trend has been pretty favorable too, with estimates moving from a loss of 12 cents per share 30 days ago to earnings of 1 cent a share today.
Current Year Estimates for AMAG
Meanwhile, AMAG Pharmaceuticals’ current year figures are also looking quite promising, with 4 estimates moving higher in the past month, compared to no downward revision. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 60 cents per share 30 days ago to a loss of 30 cents per share today, an increase of 50.0%.
Bottom Line
The stock has also started to move higher lately, adding 13.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment